Gelteq Announces USD $3.5 Million Strategic Debt Financing to Accelerate Commercialization and Support Revenue Growth

Gelteq (ASX:GELS) arranged up to USD $3.5 million in strategic debt financing to fund commercialization, expand clinical trials and support revenue-generating opportunities.

Rhea-AI Summary

Gelteq (ASX:GELS) arranged up to USD $3.5 million in strategic debt financing to fund commercialization, expand clinical trials and support revenue-generating opportunities. The facility provides $1 million at closing and a further $2.5 million subject to shareholder approval expected in June 2026.

The structure includes at least six months with no repayments, which Gelteq believes will preserve operational runway while it scales pharmaceutical and nutraceutical programs and accelerates sales execution across key markets.

Positive

• Debt facility of up to USD $3.5 million for growth initiatives
• USD $1 million provided at closing, improving near-term liquidity
• No debt repayments for at least six months from closing
• Financing targeted to expand clinical trials and commercialization efforts

Negative

• Additional leverage from new debt financing instead of non-debt capital
• Remaining USD $2.5 million contingent on shareholder approval in June 2026

Argus May 12 session

-4.47% close to close Open Argus

Details

News Market Reaction – GELS

In the May 12 session, GELS declined 4.47%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement outlines up to USD $3.5 million in strategic debt financing, including $1 million ...

Analysis

This announcement outlines up to USD $3.5 million in strategic debt financing, including $1 million at closing and $2.5 million subject to shareholder approval expected in June 2026. Proceeds are earmarked for clinical trial expansion, regulatory advancement, and commercialization of nutraceutical and pharmaceutical products. Investors may monitor how efficiently this capital accelerates revenue-generating programs, progress toward Nasdaq bid-price compliance, and any further financing needs given the company’s ongoing operating losses.

Key Figures

Strategic debt financing: USD $3.5 million Initial drawdown: USD $1 million Additional tranche: USD $2.5 million +2 more

Strategic debt financing

USD $3.5 million

Total facility size to support commercialization and trials

Initial drawdown

USD $1 million

Capital available on closing of the debt financing

Additional tranche

USD $2.5 million

Available upon shareholder approval of the financing

Shareholder approval timing

June 2026

Company intends to seek approval for the financing then

Repayment holiday

At least six months

No debt repayments required from closing for this period

Historical Context

5 past events · Latest: Apr 02

5 events

1. Apr 02

   Preliminary results

   24h Move

   -8.0%

   Reported net revenue up 45% to $4.5M and higher capacity outlook.

2. Feb 11

   Manufacturing partnership

   24h Move

   -1.4%

   MoU for U.S. manufacturing and global distribution of gel formulations.

3. Jan 13

   Preclinical data

   24h Move

   +6.4%

   Positive preclinical CBD data with >22% bioavailability improvement vs oil.

4. Dec 16

   Sports partnership

   24h Move

   +0.1%

   Asia sports partnership plus China agreement with $1.3M minimum orders.

5. Dec 09

   China sales deal

   24h Move

   -0.9%

   Three‑year China distribution agreement with minimum ~$1.3M revenue.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

debt financing, clinical trial, regulatory pathways, nutraceutical

4 terms

debt financing financial

"today announced that it has secured strategic debt financing of up to USD $3.5"

Debt financing is the process of raising money by borrowing it from lenders, which must be paid back over time with interest. It is like taking a loan to fund a project or investment, allowing a business or individual to access funds immediately while agreeing to repay the amount borrowed later. For investors, understanding debt financing helps assess how a company funds its operations and manages financial risk.

clinical trial medical

"expand clinical trial activity and execute on existing revenue opportunities."

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

regulatory pathways regulatory

"programs as Gelteq advances its pharmaceutical products through regulatory pathways and"

Regulatory pathways are the official routes companies follow to win government approval for products such as drugs, medical devices, or other regulated offerings. They matter to investors because the chosen route determines how long approval takes, how much testing and expense are required, and how quickly a product can reach customers—much like choosing between a standard building permit and an expedited emergency permit affects cost, speed, and risk.

nutraceutical medical

"ramping up commercialization of its nutraceutical products."

A nutraceutical is a product made from food ingredients that is promoted to provide health benefits beyond basic nutrition — for example vitamins, herbal extracts, fortified foods, and dietary supplements. Investors watch nutraceuticals because they sit between food and medicine: consumer demand, limited regulation, and claims about health effects can drive fast sales and higher margins but also create liability, regulatory risk, and uncertainty about long‑term efficacy, which affect company value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MELBOURNE, Australia, May 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced that it has secured strategic debt financing of up to USD $3.5 million to accelerate its commercialization, expand clinical trial activity and execute on existing revenue opportunities.

Gelteq intends to use the proceeds of the financing to advance its key strategic initiatives, including scaling up clinical trial programs as Gelteq advances its pharmaceutical products through regulatory pathways and ramping up commercialization of its nutraceutical products. Gelteq believes the financing will strengthen its operational scalability and enable the Company to accelerate sales execution across key markets. In addition, the proceeds are expected to enable Gelteq to effectively deploy greater resources across revenue-generating opportunities, supporting both ongoing trials and the transition of key products into scalable commercial programs.

“This debt financing marks an important step forward in advancing our commercial strategy,” said Nathan Givoni, CEO of Gelteq. “With additional growth capital now secured, we believe we are well-positioned to accelerate our clinical programs, scale operations, and drive broader market adoption of our Gelteq® technology. The Company has invested significantly in R&D to establish and validate our technology, and this financing enables us to further accelerate our transition toward commercialization, revenue generation, and market expansion.”

The debt financing will provide Gelteq USD $1 million on closing, with a further USD $2.5 million available to Gelteq upon receipt of shareholder approval for the financing, which the Company intends to seek in June 2026. The financing structure provides the Company with near-term growth capital while preserving operational runway during the next phase of commercialization. The debt financing includes no repayments for at least six months from closing, providing the Company with operational flexibility during the next phase of commercialization.

About Gelteq Ltd.

Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a biotechnology company that has developed a novel drug delivery platform in an ingestible gel form. Gelteq® technology, a proprietary delivery technology, is designed to improve how active ingredients are formulated, stabilised and absorbed by the body. Gelteq specializes in research and development, product creation and manufacturing for partners across pharmaceutical, consumer health and animal health markets. Gelteq® technology aims to address challenges associated with conventional drug and nutrient delivery by enhancing bioavailability, improving patient compliance, and enabling precise dosing. For more information, visit www.gelteq.com

Gelteq Contact:
Investor Relations
Matt Kreps, Darrow Associates IR
+1-214-597-8200
mkreps@darrowir.com

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on November 17, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Gelteq (GELS) announce on May 12, 2026 about new financing?

Gelteq announced up to USD $3.5 million in strategic debt financing. According to Gelteq, the capital will fund commercialization, expand clinical trial activity, and support existing revenue opportunities as the company advances pharmaceutical and nutraceutical products through regulatory and commercial pathways.

How is Gelteq’s USD $3.5 million debt financing for GELS structured?

The financing provides USD $1 million at closing and up to $2.5 million after shareholder approval. According to Gelteq, this staged structure offers near-term growth capital while preserving operational runway during the next phase of commercialization and clinical development.

When will Gelteq seek shareholder approval for the additional USD $2.5 million debt financing for GELS?

Gelteq plans to seek shareholder approval for the additional USD $2.5 million in June 2026. According to Gelteq, this approval is required before accessing the second tranche of the facility beyond the initial USD $1 million received at closing.

How will the USD $3.5 million debt financing support Gelteq’s commercialization and revenue growth?

The financing is intended to accelerate commercialization and support revenue-generating opportunities. According to Gelteq, proceeds will ramp up nutraceutical product commercialization, strengthen sales execution in key markets, and help transition selected products into scalable commercial programs alongside ongoing trials.

What impact will Gelteq’s new debt financing have on its clinical trial programs?

Gelteq expects the capital to expand its clinical trial activity. According to Gelteq, funds will scale clinical trial programs as pharmaceutical products move through regulatory pathways, aiming to support both ongoing studies and the advancement of its Gelteq technology toward commercialization.

Does the Gelteq (GELS) debt financing include an initial repayment holiday?

Yes, there are no repayments for at least six months from closing. According to Gelteq, this repayment holiday is designed to provide operational flexibility and preserve runway while the company focuses on commercialization, scaling operations, and clinical program acceleration.

What does Gelteq’s CEO say about the strategic importance of the USD $3.5 million financing for GELS shareholders?

CEO Nathan Givoni describes the financing as an important step in advancing Gelteq’s commercial strategy. According to Gelteq, the added growth capital should help accelerate clinical programs, scale operations, and drive broader market adoption of the company’s Gelteq-branded technology.